Unique ID issued by UMIN | UMIN000002930 |
---|---|
Receipt number | R000002882 |
Scientific Title | pilot study of hepatic resection followed by intraarterial 5-fluorouracil/cisplatin combination therapy for advanced hepatocellular carcinoma with vascular invasion |
Date of disclosure of the study information | 2009/12/22 |
Last modified on | 2013/07/18 20:20:51 |
pilot study of hepatic resection followed by intraarterial 5-fluorouracil/cisplatin combination therapy for advanced hepatocellular carcinoma with vascular invasion
hepatic resection followed by low dose FP for HCC with vascular invasion
pilot study of hepatic resection followed by intraarterial 5-fluorouracil/cisplatin combination therapy for advanced hepatocellular carcinoma with vascular invasion
hepatic resection followed by low dose FP for HCC with vascular invasion
Japan |
hepatocellular carcinoma with vascular invasion
Hepato-biliary-pancreatic medicine |
Malignancy
NO
To elucidate the efficacy of hepatic resection followed by intraarterial 5-fluorouracil/cisplatin combination therapy for advanced hepatocellular carcinoma with vascular invasion
Efficacy
overall survival
1) time to progression
2) safety
3) response rate
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine | Maneuver |
1) hepatic resection
2) low dose FP
One course of chemotherapy represented 2 weeks. 5FU (300 mg/m2/24h) was administered using a mechanical infusion pump on days 1-5 of the first and second weeks. CDDP (6 mg/m2/0.5h) was administered using a mechanical infusion pump on days 1-5 of the first and second weeks. A 2- to 4-week rest period of no treatment was allowed after each treatment course. Treatment was repeatec unless HCC reveales progressive disease (acording to RECIST).
20 | years-old | <= |
Not applicable |
Male and Female
1) Diagnosis of HCC was confirmed histopathologically or clinically.
2) no adaptation of liver transplantation and local abration.
3) with Vp3/4 or Vv2/3 or B3/4
4) without uncontrollable ascites
5) without hepatic coma
6) PS 0-1
7) chronic hepatitis or Child-Pugh A
8)
WBC > 3000/mm3
Plt > 80000/mm3
Hb > 10.0 g/dl
Total Bilirubin < 2.0 mg/dl
Albumin > 3 g/dl
Creatine < 1.2mg/dl
Prothromin time > 60 percentage
1) With other malignant disease.
2) A pregnant woman, or a woman suspected of pregnancy.
3) With severe infectious disease.
4) With history of severe allergy.
5) With severe renal function disease. 6) With severe allergy for 5FU or CDDP.
7) With severe bone marrow supression.
20
1st name | |
Middle name | |
Last name | Kazuaki Chayama |
Hiroshima University
Department of Medicine and Molecular Science, Division of Frontier Medical Science, Programs for Biomedical Research, Graduate School of Biomedical Sciences
1-2-3 Kasumi, Minami-ku, Hiroshima
1st name | |
Middle name | |
Last name |
Hiroshima University
Department of Medicine and Molecular Science, Division of Frontier Medical Science, Programs for Bio
Department of Medicine and Molecular Science, Division of Frontier Medical Science, Programs for Biomedical Research, Graduate School of Biomedical, Hiroshima University
Department of Medicine and Molecular Science, Division of Frontier Medical Science, Programs for Biomedical Research, Graduate School of Biomedical, Hiroshima University
Self funding
NO
2009 | Year | 12 | Month | 22 | Day |
Unpublished
Terminated
2009 | Year | 09 | Month | 01 | Day |
2009 | Year | 09 | Month | 01 | Day |
2012 | Year | 03 | Month | 01 | Day |
2009 | Year | 12 | Month | 22 | Day |
2013 | Year | 07 | Month | 18 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000002882